Hemophilia Treatment Market to Reach US$21.3 Bn in 2027, Rise in Blood Clotting and Bleeding-related Diseases Major Growth Contributor

May 2022

A steady rise in diseases related to blood clotting and bleeding have been recorded, unveiling significant growth prospects for the hemophilia treatment market. Over the recent past, the incidence of hemophilia, a rare or orphan X-linked recessive bleeding disorder, has been on the rise. Hemophilia creates a deficiency of protein known as clotting factor that prevents blood from clotting properly. The disease is divided into three types, such as Hemophilia A, hemophilia B, and acquired hemophilia. Evidently, 70% of hemophilia cases are caused by genetic inheritance. Among all the hemophilia cases, 80%-85% recorded cases are for hemophilia A, while hemophilia B accounts for a mere 15%-20% of cases. Being prevalent in a relatively small segment of the global population, tests have been conducted across a targeted population.

According to Fairfield Market Research, the hemophilia treatment market revenue charts are experiencing steep inclines, poised to reach US$21.3 Bn in 2027 as against US$14.7 Bn in 2021. The market is highly stable, growing at a sophisticated CAGR of 5.2% during the assessment period of 2022 and 2027. Such positive figures point towards lucrative opportunities floating across the market. Going forward, the key market players are likely to bank on open innovation, strategic partnerships, and aggressive pursuit of novel therapeutics to gain a strong foothold in the global market.

Major Trends Across Global Hemophilia Treatment Market

  • In 2022, the market in North America was valued at around US$6.4 Bn, which is poised to reach US$7.8 Bn in 2027, sustaining the leading market position

  • Based on application, the prophylaxis segment is set to reach US$8 Bn by 2027 end

  • During the assessment period, Hemophilia A is anticipated to generate approximately US$15 Bn value

Introduction of Novel Therapeutics to Serve as Critical Enabler for Hemophilia Treatment Market

Tremendous efforts are being made to improve the treatment of people with hemophilia. In this regard, novel therapeutics have been developed including targeting natural anticoagulant pathways, biphasic antibodies (FVIII mimetics), extended half-life factor concentrates (FVIII/FIX), and gene therapy/editing. Furthermore, the development of modern clotting factor concentrates (CFCs) has significantly reduced the burden of care for patients.

Extended half-life CFCs have facilitated the maintenance of high factor trough levels on regular replacement therapy. The advent of Hemlibra (emicizumab) demonstrates greater efficacy and convenience in dosage, making it most prominent among other older hemophilia treatments. All factors combined; the hemophilia treatment market is set to witness robust growth in the coming years.

North America Reigns Supreme with Robust Presence of Major Market Players

With the greatest share in the global hemophilia treatment market revenue, North America has cemented its regional dominance. The market is projected to grow at a steady CAGR of 4% during the forecast period. This growth is strongly backed by the sound availability of major market players, a rise in GDP per capita income, and government rebates. On the flip side, Asia Pacific has emerged as a sound competitor with accessibility to modern treatments at competitively low prices. The region shows promising growth prospects, witnessing a stable CAGR of 7.2% over the assessment period.

Major Market Players

Bayer AG, BioMarin Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Grifols S.A., Sanofi, Takeda Pharmaceuticals Company Ltd., CSL Behring, Medexus Pharmaceuticals Inc., Novo Nordisk, Octapharma AG, Pfizer Inc.